JAZZ News and Press, Jazz Pharmaceuticals plc From 07/23/21

Biotech stocks had a muted first half with the S&P Biotech Index down year-to-date, and more than 20% lower from its mid-February peak. The decline in biotech stocks coincided with a spike in interest rates and stabilizing interest rates can provide a boost to valuations. M&am...

National Comprehensive Cancer Network® Adds Newly Approved Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) to Clinical Practice Guidelines in Oncology for Acute Lymphoblastic Leukemia PR Newswire DUBLIN , July 22, 2021 /PRNewswire/ --&#...

Since Fintepla's launch, shares of Zogenix have continued to slide. This is, primarily, due to unimpressive Fintepla adoption two quarters in and an underperforming biotechnology sector. Last quarter, Fintepla saw 53% quarter-over-quarter growth, with revenues coming in at $...

Jazz Pharmaceuticals to Report 2021 Second Quarter Financial Results on August 3, 2021 PR Newswire DUBLIN , July 20, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2021 second quarter financial results on...

Investing In The Medical Cannabis Industry Medical marijuana stocks have become an area of extensive growth for the cannabis industry. Currently in the US 37 states have implemented medical cannabis legalization in 2021. Across the world, cannabis is becoming much more accepted in t...

Jazz Pharmaceuticals Announces Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) Investor Webcast on July 20, 2021 PR Newswire DUBLIN , July 13, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will...

A financial analyst has issued a new report full of excitement about the US cannabis marketplace and its current players. Also this week, a Canadian exchange-traded fund (ETF) operator completed its quarterly rebalancing of two cannabis funds, meaning new names were added. Keep ...

janiecbros/E+ via Getty Images Biotech M&A is poised to heat up again as shares of the SPDR S&P Biotech’s (XBI) have fallen about 25% from their February highs, according to Jefferies. Biotech deals may pick up after a 3-6 month of a large "drawdown" and as prices "normalize" f...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pharmaceutical companies can be a great investment. Especially for investors in search of long-term growth candidates for their portfolio. A successful new drug or treatment is covered by patents for 20 years in the U.S. m...

Health Canada has approved Jazz Pharmaceuticals' (JAZZ) Vyxeos for the treatment of certain adult patients with acute myeloid leukemia  ((AML)).The approval allows for the treatment of newly diagnosed therapy-related AML ((t-AML)) or AML with myelodysplasia-related changes ((AML-MRC...